Dolasetron is a nonbenzamide antiematic drug approved by the FDA in 1997 for the prevention and treatment of postoperative nausea and vomiting. It works by blocking the action of serotonin at 5-HT3 receptors. Dolasetron is administered as a prodrug that is metabolized in vivo into its active metabolite, hydrodolasetron. Common side effects include dizziness, headache, blurred vision, constipation, and diarrhea.